Brief: Hanmi Pharm's Partner Co Lilly To Return Exclusive Licence To Hanmi Pharm
Jan 23 (Reuters) - Hanmi Pharm Co Ltd 128940.KS :
* SAYS PARTNER CO ELI LILLY AND CO DECIDES TO RETURN
EXCLUSIVE
LICENCE OF ARTHRITIS DRUG TO HANMI PHARM
* SAYS LILLY ABANDONED TRIALS OF ARTHRITIS DRUG ON LOW
CHANCE OF
SHOWING EFFICACY IN FEB 2018
* SAYS LILLY DECIDED TO RETURN LICENCE AFTER REVIEWING TRIAL
DATA
AND ARTHRITIS DRUG MARKET IN JAN
Source text for Eikon: https://bit.ly/2S14LMF
Further company coverage: 128940.KS
((Reuters Messaging: joori.roh.thomsonreuters.com@reuters.net))
Recent news on Hanmi Pharm
See all newsBrief: Hanmi Pharm To Cancel 28 Billion Won Worth Of Own Shares
Brief: Hanmi Pharm Q3 Operating Profit 37.8 Billion Won, Down 31.3% From Year Earlier
Brief: Hanmi Pharm Co Signs License Out Agreement With Genetech Inc. In U.S.
Brief: Hanmi Pharm Co Enters License Agreement With Eli Lilly For Sonefpeglutide
Brief: Hanmi Pharm Co Ltd Wins 53 Billion Won Order